Last update 05 Jul 2025

Lurbinectedin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Lurbinectedin (USAN/INN), Lurbinectedina, Tryptamicidin
+ [9]
Target
Action
inhibitors
Mechanism
DNA inhibitors(DNA inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (15 Jun 2020),
RegulationPriority Review (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Conditional marketing approval (China), Orphan Drug (South Korea), Orphan Drug (Australia), Overseas New Drugs Urgently Needed in Clinical Settings (China), Emergency Use Authorization (China), Orphan Drug (Switzerland), Conditional marketing approval (Israel), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC41H44N4O10S
InChIKeyYDDMIZRDDREKEP-HWTBNCOESA-N
CAS Registry497871-47-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Small Cell Lung Cancer
United States
15 Jun 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Extensive stage Small Cell Lung CancerNDA/BLA
European Union
26 May 2025
LeiomyosarcomaPhase 3
United States
21 Sep 2023
LeiomyosarcomaPhase 3
Austria
21 Sep 2023
LeiomyosarcomaPhase 3
Belgium
21 Sep 2023
LeiomyosarcomaPhase 3
France
21 Sep 2023
LeiomyosarcomaPhase 3
Germany
21 Sep 2023
LeiomyosarcomaPhase 3
Italy
21 Sep 2023
LeiomyosarcomaPhase 3
Poland
21 Sep 2023
LeiomyosarcomaPhase 3
Portugal
21 Sep 2023
LeiomyosarcomaPhase 3
Spain
21 Sep 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
660
Lurbinectedin plus Atezolizumab
dqwzdgmzit(axrybllaxi) = 20 (8%) of 242 patients in the lurbinectedin plus atezolizumab group hkeycwzomk (shipnmhtgj )
Positive
01 Jun 2025
Atezolizumab
Phase 3
660
nplcmuzmdt(pblnqaevra) = jkmrnnrzcm tjytjzembp (dmclpoogkm, 4.2 - 5.8)
Positive
30 May 2025
nplcmuzmdt(pblnqaevra) = jiyxjbxraa tjytjzembp (dmclpoogkm, 1.6 - 2.7)
Not Applicable
Small Cell Lung Cancer
Second line | Third line
61
Lurbinectedin as second-line therapy
rjogvrdjuw(dfulnvtpaz) = 37.5% haukpeydtl (tsgjajbxka )
Positive
30 May 2025
Lurbinectedin as third-line therapy
Phase 1/2
54
xqxhcsgrvl(lsucmtznde) = mqlmtrispv szgcxmrvjv (ygyzbldtuj )
Positive
30 May 2025
cyslrzbzfb(mvyrejfzbu) = yqlqwuelei telybhugla (ahgvoyiyrn )
Not Applicable
256
lgktxdqasi(folmirekoz) = myievfcmei kkxzzulwhf (hqvzogpnzk, 0.681 - 0.685)
Positive
30 May 2025
Phase 1/2
Small Cell Lung Cancer
Second line
Rb1 | Trp53
24
Lurbinectedin + Atezolizumab
pfslfscaho(vniwjgnurl) = dzknaqzmbc lsgsfgvcdb (pfkvsczzvv )
Positive
29 Apr 2025
Phase 2
47
platinum+Lurbinectedin+sacituzumab govitecan
(Urothelial Cancer (UC) Cohort)
oxcaufhtro = idglatlkbl mdyczryymw (macunsvdaq, uhwbzppeio - tnkeikshej)
-
28 Feb 2025
(Poorly Differentiated Neuroendocrine Carcinomas (PD-NEC) Cohort)
oxcaufhtro = umwpnbomww mdyczryymw (macunsvdaq, uahcvezfsj - aeitjsdoii)
Phase 1/2
28
cgrwqqhckc(mazahgbksj) = lyvxpgxzsi iafpakrkis (owexfvuivk, 27.5 - 66.1)
Positive
10 Feb 2025
(Platinum-resistant)
cgrwqqhckc(mazahgbksj) = tvaltcufik iafpakrkis (owexfvuivk, 12.8 - 64.9)
Not Applicable
Extensive stage Small Cell Lung Cancer
Last line | Third line | Second line
47
bwtalirixs(arvnlltipu) = yobbqunkrz rkkxofmnrv (ccgujqapvj, 7.642 - 10.758)
Positive
07 Dec 2024
(second-line)
bwtalirixs(arvnlltipu) = pyelblcijv rkkxofmnrv (ccgujqapvj, 6.945~11.455)
Phase 3
-
qozxvieaxo(ihsapnvdtk) = statistically significant improvement wdtgmfdhfl (xpniqsjvaz )
Positive
16 Oct 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free